Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy.
We describe two cases of interstitial lung disease in patients with non-Hodgkin's lymphoma who were treated with combination chemotherapy including mitozantrone. In both we had radiological and histological evidence of interstitial lung disease, with patterns of organizing pneumonia and hypersensitivity without a clear aetiological agent. Clinical resolution occurred on withdrawal of chemotherapy. One patient required a course of corticosteroid treatment. To date, both patients are well and in remission, and there has been no recurrence of their respiratory disease. We postulate that these observations are hitherto undescribed pulmonary abnormalities secondary to mitozantrone therapy.
Tomlinson
J
J
Musgrove Park Hospital, Taunton, UK.
Tighe
M
M
Johnson
S
S
Stone
R
R
Nicholson
A G
AG
Rule
S
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects*; D011014:Pneumonia / Q000139:chemically induced*; D011239:Prednisolone / Q000008:administration & dosage
D000970:Antineoplastic Agents; D002699:Chlorambucil; D011239:Prednisolone; D008942:Mitoxantrone